Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease,…

Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager

Plus, news about Stada, Convalife Pharmaceuticals, Mabwell Bioscience, Zenas BioPharma, vTv Therapeutics, OMass Therapeutics and Merck.

Clinical Focus: Zymeworks Discontinues Development of ZW171 in Phase 1 Trial

Zymeworks discontinues ZW171 clinical development after phase 1 trial reveals unfavorable benefit-risk profile, shifting focus to other promising candidates.